BRIEF published on 07/07/2025 at 15:05, 8 months 18 days ago Applied DNA Sciences se conforme aux normes de cotation du Nasdaq Biotechnologie Sciences Appliquées De L'ADN Conformité Au Nasdaq Technologies De L'ADN LineaRx
BRIEF published on 07/07/2025 at 15:05, 8 months 18 days ago Applied DNA Sciences Complies with Nasdaq Listing Standards Biotechnology Nasdaq Compliance Applied DNA Sciences DNA Technologies LineaRx
PRESS RELEASE published on 07/07/2025 at 15:00, 8 months 18 days ago Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements Applied DNA Sciences regains compliance with Nasdaq listing rule requiring minimum bid price of $1.00 per share. Company's securities to remain listed on Nasdaq Capital Market Nasdaq Compliance Applied DNA Sciences Nasdaq Capital Market Minimum Bid Price PCR-based DNA Technologies
BRIEF published on 06/17/2025 at 22:15, 9 months 8 days ago Transition de direction chez Applied DNA : le Dr Hayward, PDG, prend sa retraite Biotechnologie Changement De Direction Valeur Actionnariale ADN Appliqué Judy Murrah
BRIEF published on 06/17/2025 at 22:15, 9 months 8 days ago Leadership Transition at Applied DNA as CEO Dr. Hayward Retires Biotechnology Shareholder Value Leadership Change Applied DNA Judy Murrah
PRESS RELEASE published on 06/17/2025 at 22:10, 9 months 8 days ago Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward Judy Murrah appointed Chairperson and CEO of Applied DNA Sciences, succeeding Dr. James A. Hayward. Experienced executive aims to lead company's innovative DNA technologies CEO Appointment Applied DNA Sciences DNA Technologies Judy Murrah Dr. James A. Hayward
BRIEF published on 05/15/2025 at 22:10, 10 months 10 days ago Applied DNA Sciences enregistre une croissance modeste de ses revenus au deuxième trimestre 2025 Croissance Des Revenus Restructuration Stratégique Résultats Financiers Du Deuxième Trimestre Tendances Biopharmaceutiques Technologie De L'ADN
BRIEF published on 05/15/2025 at 22:10, 10 months 10 days ago Applied DNA Sciences Sees Modest Revenue Growth in Q2 2025 Revenue Growth Strategic Restructuring Q2 Financial Results DNA Technology Biopharma Trends
PRESS RELEASE published on 05/15/2025 at 22:05, 10 months 10 days ago Applied DNA Reports Second Quarter Fiscal 2025 Financial Results Applied DNA Sciences, Inc. (NASDAQ:APDN) reports a 44% Y/Y increase in LineaRx segment revenues contributing to a 6% total revenue growth. Strategic priorities and financial highlights for Q2 2025 disclosed Financial Results Strategic Priorities Applied DNA Sciences LineaRx Segment Therapeutic DNA Production
BRIEF published on 05/14/2025 at 17:35, 10 months 11 days ago Applied DNA Sciences publiera ses résultats financiers du deuxième trimestre et organisera une mise à jour pour les investisseurs Sciences Appliquées De L'ADN Conférence Téléphonique Pour Les Investisseurs Priorités Stratégiques Rediffusion Du Webcast Résultats Financiers Du Deuxième Trimestre 2025
Published on 03/26/2026 at 08:05, 1 hour 34 minutes ago Vanta Announces U.S. Ticker Symbol Change to VNTXF
Published on 03/26/2026 at 04:55, 4 hours 44 minutes ago Vanta Announces Capital Markets Initiatives to Strengthen Financial Position and Support Growth Initiatives
Published on 03/26/2026 at 00:40, 8 hours 59 minutes ago Challenger RC Resource Upgrade Drilling Complete
Published on 03/26/2026 at 00:30, 9 hours 9 minutes ago Nano One Highlights Recent Objectives & Reports Fourth Quarter 2025 Results
Published on 03/25/2026 at 19:15, 14 hours 24 minutes ago Gemina Laboratories Ltd. Announces Delisting from the CSE
Published on 03/26/2026 at 09:20, 18 minutes ago yoummday Wins a Texas Instruments 2025 Supplier Excellence Award
Published on 03/26/2026 at 09:05, 33 minutes ago Rockwell Automation Showcases Autonomous Industrial Operations at Hannover Messe 2026
Published on 03/26/2026 at 09:00, 38 minutes ago Original-Research: ZEAL Network SE (von NuWays AG): BUY
Published on 03/26/2026 at 09:00, 38 minutes ago Original-Research: INDUS Holding AG (von NuWays AG): BUY
Published on 03/26/2026 at 07:30, 2 hours 9 minutes ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/26/2026 at 07:30, 2 hours 9 minutes ago BIOPHYTIS ET LYNXKITE INVITÉS À LA CONFÉRENCE NVIDIA : L’IA AU SERVICE DE LA LONGÉVITÉ
Published on 03/25/2026 at 18:53, 14 hours 45 minutes ago CIS - Transfert Contrat de Liquidité Portzamparc - 25.03.2026
